ArticleBritish journal of cancer2026
The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLung cancer is the leading cause of cancer-related mortality, with brain metastases (BMs) significantly worsening prognosis. While Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), robust prognostic tools are still lacking.
methodsThe Brain-Lung Immunotherapy Prognostic (BLIP) score was developed using a retrospective cohort of NSCLC patients with BMs treated with ICIs at Karolinska University Hospital, Sweden. Prognostic factors were identified via univariate and multivariable Cox regression. Internal validation employed bootstrap resampling, penalized Cox regression and ROC analysis. External validation was conducted using an independent cohort from Sotiria Thoracic Diseases Hospital of Athens, Greece.
resultsOf 1844 screened patients, 131 from Karolinska and 109 from Sotiria were included. Key variables were histology, age at BM diagnosis, and number of BMs. The BLIP score stratified patients into "Good" and "Poor" prognosis groups, with median overall survival (OS) of 14.5 and 7 months (hazard ratio [HR]: 0.4; p < 0.0001). External validation confirmed these findings (HR: 0.5; p = 0.0099).
conclusionThe BLIP score is a validated prognostic tool for NSCLC patients with BMs receiving ICIs. Incorporating clinical factors, it enhances personalized risk stratification. HIGHLIGHTS: The BLIP score is a novel prognostic tool for NSCLC with brain metastases undergoing immunotherapy. Integrates key clinical factors like histology, age, and metastasis count. Internal validation demonstrates strong prognostic power and reliability. External validation shows effectiveness across diverse patient populations. Stratifies patients into "Good" and "Poor" groups, aiding in personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.